News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
